프럭토올리고당(FOS) 관련 과민성 대장 증후군(IBS)
D 연구 예비 연구(실험실 연구, 증례 보고)만 존재합니다.결과가 혼재되어 있습니다. 저용량(5g)은 도움이 될 수 있으나 고용량은 빠른 발효로 인해 팽만감을 악화시킬 수 있습니다.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dfructooligosaccharides\u0026condition\u003Dibs';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
D
결론
결과가 혼재되어 있습니다. 저용량(5g)은 도움이 될 수 있으나 고용량은 빠른 발효로 인해 팽만감을 악화시킬 수 있습니다.
Key Study Findings
Other
FODMAP Profile of Wholegrain Pasta.
Dose: None
vs: None
Outcome: FODMAP compound content in pasta (analytical)
효과: None
None
대상 집단: Commercially available pasta products (analytical study)
Randomized Controlled Trial
n=9
12 weeks
Modification of the Low FODMAP Diet Is Feasible in the Treatment of Irritable Bowel Syndrome: …
Dose: None
vs: Baseline; crossover between 3 diets
Outcome: Birmingham IBS questionnaire symptom score
효과: 75% relief on low FOS+GOS; 62.5% on FODMAP
p<0.05
대상 집단: IBS patients (Rome IV criteria)
Other
Biotechnological Tools for the Production of Low-FODMAP Wholegrain Wheat and Rye Cookies and Crackers.
Dose: None
vs: Standard wholegrain flour products
Outcome: FODMAP content reduction in cookies and crackers
효과: Up to 99.5% FODMAP reduction (wheat malt)
None
대상 집단: Laboratory food science study (no human subjects)
Randomized Controlled Trial
12 weeks
Double-blind
Efficacy and Safety of a Mixture of Microencapsulated Sodium Butyrate, Probiotics, and Short Chain Fructooligosaccharides …
Dose: None
vs: Placebo
Outcome: Quality of life
효과: None
p = 0.023
대상 집단: IBS patients
In Vitro
Microbial inulinase promotes fructan hydrolysis under simulated gastric conditions.
Dose: None
vs: None
Outcome: None
효과: None
None
대상 집단: None
Controlled Clinical Trial
n=54
3.0 weeks
[Clinical efficacy of a modern probiotic for the correction of intestinal microflora in patients with …
Dose: 350 mg
vs: None
Outcome: IBS symptom improvement
효과: None
None
대상 집단: Irritable bowel syndrome with diarrhea and antibiotic-associated diarr
Key Statistics
2
연구
150
참여자
↔
Mixed
D
등급
Referenced Papers
Foods (Basel, Switzerland)
2025
3 인용
Foods (Basel, Switzerland)
2025
1 인용
Gastroenterology research and …
2025
Journal of clinical …
2024
4 인용
Frontiers in nutrition
2023
8 인용
Voprosy pitaniia
2023
Carbohydrate polymers
2022
77 인용
FASEB journal : …
2022
16 인용
Journal of clinical …
2022
12 인용
Nutrients
2022
8 인용
Expert review of …
2022
8 인용
Food chemistry: X
2021
64 인용
Foods (Basel, Switzerland)
2021
10 인용
Nutrients
2020
78 인용
Journal of agricultural …
2018
13 인용
Neurogastroenterology and motility
2017
131 인용
Nutrition journal
2017
10 인용
Voprosy pitaniia
2013
The American journal …
2000
136 인용
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
일반적으로 사용되는 용량
- general:
- 2-10 g/day
- prebioticeffect:
- 5-8 g/day for bifidogenic effect
- constipationsupport:
- 5-10 g/day
상한량: Well-tolerated up to 20 g/day; start low to avoid excess gas
연구에서 사용된 용량
| 용량 | 기간 | 효과 | N |
|---|---|---|---|
| None | -- | Neutral | -- |
| None | 12 weeks | Positive | 9 |
| None | -- | Positive | -- |
| None | 12 weeks | Positive | -- |
| None | -- | Mixed | -- |
| 350 mg | 3.0 weeks | Positive | 54 |
| None | -- | Mixed | -- |
| None | -- | Negative | -- |
권장 복용 시간: With meals; divide doses throughout the day
Safety & Side Effects
보고된 부작용
- ⚠ Gas, bloating, and flatulence (dose-dependent; more common above 10 g/day)
- ⚠ Abdominal cramping at higher doses
- ⚠ May worsen IBS symptoms in FODMAP-sensitive individuals
- ⚠ Loose stools at excessive doses
알려진 상호작용
- ● Other FODMAPs (cumulative fermentation effect in sensitive individuals)
- ● Blood sugar-lowering medications (FOS may modestly affect glycemic response)
- ● Calcium supplements (FOS may enhance calcium absorption)
일일 최대 섭취 허용량: Well-tolerated up to 20 g/day; start low to avoid excess gas
건강기능식품을 복용하기 전에 반드시 의료 전문가와 상담하십시오.
Frequently Asked Questions
Does 프럭토올리고당(FOS) help with 과민성 대장 증후군(IBS)?
Based on 2 studies with 150 participants, there is preliminary evidence that needs more research that 프럭토올리고당(FOS) may support 과민성 대장 증후군(IBS) management. Our evidence grade is D (Very Early Research).
How much 프럭토올리고당(FOS) should I take for 과민성 대장 증후군(IBS)?
Studies have used various dosages. A commonly studied range is 2-10 g/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of 프럭토올리고당(FOS)?
Reported side effects may include Gas, bloating, and flatulence (dose-dependent; more common above 10 g/day), Abdominal cramping at higher doses, May worsen IBS symptoms in FODMAP-sensitive individuals, Loose stools at excessive doses. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for 프럭토올리고당(FOS) and 과민성 대장 증후군(IBS)?
We rate the evidence as Grade D (Very Early Research). This rating is based on 2 peer-reviewed studies with 150 total participants. The overall direction of effect is mixed.
Related Evidence
관련 다른 성분: 과민성 대장 증후군(IBS)
프럭토올리고당(FOS) 다른 건강 상태에 대한 근거
References
- [1] Aleksandra M Torbica et al.. Foods. 2025. FODMAP Profile of Wholegrain Pasta. doi:10.3390/foods14040667 PubMed
- [2] Aleksandra M Torbica et al.. Foods. 2025. Biotechnological Tools for the Production of Low-FODMAP Wholegrain Wheat and Rye Cookies and Crackers. doi:10.3390/foods14040582 PubMed
- [3] Line Graser Jensen et al.. Gastroenterol Res Pract. 2025. Modification of the Low FODMAP Diet Is Feasible in the Treatment of Irritable Bowel Syndrome: A Randomised Crossover Study. doi:10.1155/grp/4152978 PubMed
- [4] Anita Gąsiorowska et al.. J Clin Med. 2024. Efficacy and Safety of a Mixture of Microencapsulated Sodium Butyrate, Probiotics, and Short Chain Fructooligosaccharides in Patients with Irritable Bowel … doi:10.3390/jcm14010006 PubMed
- [5] Justin L Guice et al.. Front Nutr. 2023. Microbial inulinase promotes fructan hydrolysis under simulated gastric conditions. doi:10.3389/fnut.2023.1129329 PubMed
- [6] V N Drozdov et al.. Vopr Pitan. 2023. [Clinical efficacy of a modern probiotic for the correction of intestinal microflora in patients with irritable bowel syndrome with diarrhea … doi:10.33029/0042-8833-2023-92-4-92-103 PubMed
- [7] Ashinshana U Illippangama et al.. Carbohydr Polym. 2022. Inulin as a functional ingredient and their applications in meat products. doi:10.1016/j.carbpol.2021.118706 PubMed
- [8] J B J Kamphuis et al.. FASEB J. 2022. Increased fermentable carbohydrate intake alters colonic mucus barrier function through glycation processes and increased mast cell counts. doi:10.1096/fj.202100494RRR PubMed
- [9] Anita Gąsiorowska et al.. J Clin Med. 2022. Effects of Microencapsulated Sodium Butyrate, Probiotics and Short Chain Fructooligosaccharides in Patients with Irritable Bowel Syndrome: A Study Protocol of … doi:10.3390/jcm11216587 PubMed
- [10] Susie Jung et al.. Nutrients. 2022. A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effects of Multi-Strain Synbiotic in Patients with Functional Diarrhea and High Fecal … doi:10.3390/nu14235017 PubMed
- [11] Diego Currò. Expert Rev Gastroenterol Hepatol. 2022. Current evidence on the therapeutic use of fiber in irritable bowel syndrome. doi:10.1080/17474124.2021.1924057 PubMed
- [12] Marcel Skejovic Joehnke et al.. Food Chem X. 2021. Nutritional and anti-nutritional properties of lentil (Lens culinaris) protein isolates prepared by pilot-scale processing. doi:10.1016/j.fochx.2020.100112 PubMed
- [13] Johannes Pitsch et al.. Foods. 2021. FODMAP Fingerprinting of Bakery Products and Sourdoughs: Quantitative Assessment and Content Reduction through Fermentation. doi:10.3390/foods10040894 PubMed
- [14] Barbara Skrzydło-Radomańska et al.. Nutrients. 2020. The Effectiveness of Synbiotic Preparation Containing Lactobacillus and Bifidobacterium Probiotic Strains and Short Chain Fructooligosaccharides in Patients with Diarrhea Predominant … doi:10.3390/nu12071999 PubMed
- [15] Tobias Pöhnl et al.. J Agric Food Chem. 2018. Impact of Cultivation Method and Cultivar Selection on Soluble Carbohydrates and Pungent Principles in Onions ( Allium cepa L.). doi:10.1021/acs.jafc.8b05018 PubMed
- [16] F Azpiroz et al.. Neurogastroenterol Motil. 2017. Effects of scFOS on the composition of fecal microbiota and anxiety in patients with irritable bowel syndrome: a randomized, double … doi:10.1111/nmo.12911 PubMed
- [17] Jennifer Erickson et al.. Nutr J. 2017. Gastrointestinal tolerance of low FODMAP oral nutrition supplements in healthy human subjects: a randomized controlled trial. doi:10.1186/s12937-017-0256-3 PubMed
- [18] V I Pilipenko et al.. Vopr Pitan. 2013. [Contemporary dietotherapy of the irritable bowel syndrome]. PubMed
- [19] M Olesen et al.. Am J Clin Nutr. 2000. Efficacy, safety, and tolerability of fructooligosaccharides in the treatment of irritable bowel syndrome. doi:10.1093/ajcn/72.6.1570 PubMed
FDA 면책 조항: 이 내용은 미국 식품의약국(FDA)의 평가를 받지 않았습니다. 이 웹사이트의 제품 및 정보는 질병의 진단, 치료, 완치 또는 예방을 목적으로 하지 않습니다. 제시된 근거 등급은 발표된 동료 심사 연구에 대한 우리의 분석에 기반하며, 의학적 조언을 구성하지 않습니다. 건강기능식품 복용을 시작하기 전에 반드시 의료 전문가와 상담하십시오.